As mentioned, the present study is not able to address these questions, however future studies should address how the reduced CD25 expression observed in carriers of the MS-associated IL2RA risk allele affects CD4+ T cells IL-2 responsiveness and whether this changes T helper cells effector functions and TReg cells suppressive capacity and if there is a dual effect with soluble CD25. This evidence concerns the gene IL2 and myeloid sarcoma.